Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Jun 29, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to see how two different exercise programs can help patients with hypertrophic cardiomyopathy, a condition where the heart muscle is thicker than normal. The researchers want to compare the effects of inspiratory muscle training (IMT), which helps strengthen the muscles you use to breathe, with Baduanjin exercises, a form of gentle movement and stretching. The goal is to find out which program improves lung function, exercise ability, and overall quality of life for these patients.
To participate, you need to be over 18 years old and have a thickening of the heart muscle that is noticeable on an ultrasound or MRI. You should also be stable in your condition, meaning you don’t have any severe heart issues or other serious health problems. If you join the study, you’ll be placed in one of three groups: one will do the IMT exercises twice a day for eight weeks, while another will practice Baduanjin exercises three times a week. There will be regular check-ins to support you throughout the program. This trial is an opportunity to explore new ways to improve health and well-being for those living with this heart condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Myocardial thickness in any region of the left ventricle is 15 mm or more on echocardiography or cardiac MRI
- • Clinically and hemodynamically stable (patients with NYHA Class I and II)
- • Patients over 18 years of age
- • Patients who provide informed consent
- Exclusion Criteria:
- • Acute decompensated heart failure
- • Decreased ejection fraction (\<40%)
- • Unstable angina pectoris
- • Significant coronary artery disease (CAD)
- • Severe renal dysfunction (estimated glomerular filtration rate \<30 mL/min/m²)
- • Uncontrolled hypertension (despite medication)
- • Severe valve disease (moderate-severe aortic stenosis, advanced mitral regurgitation)
- • Severe neurological disorders causing autonomic dysfunction
- • Cognitive impairment that prevents communication
- • Recent fractures, osteoporosis, presence of tumors, pregnancy, or back and spine problems
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Rengin Demir, Prof
Study Director
Istanbul University-Cerrahpasa (IUC) Cardiology Institute
Veysel Oktay, Assoc Prof
Study Chair
Istanbul University-Cerrahpasa (IUC) Cardiology Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported